Incidence Density (ID) of Invasive Fungal Infections (IFIs) during Primary Antifungal Prophylaxis (PAP) in Acute Myeloid leukemia (AML) Patients at M.D. Anderson Cancer Center, 2009 2011

MARISA Z. R. GOMES, RUSSELL LEWIS, PHARMD, VICTOR E. MULANOVICH and DIMITRIOS KONTOYIANNIS

Author address: 

The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract: 

Background: PAP with azoles or echinocandins has been commonly used in patients with AML during immunosuppressive chemotherapy. However the ID of IFIs during PAP is not well described in a real life setting. Methods: We analyzed retrospectively 136 unselected pts with newly diagnosed AML admitted to MDACC from August-2009 to March-2011 who received PAP. The primary endpoint was the incidence of documented (definite or probable revised EORTC criteria) IFIs at 100 days after induction chemotherapy. We excluded patients who underwent SCT prior or during this period. Results: Patients had a median of 2 (range 14 drugs) different antifungal drugs as PAP; for a mean of 60 days (median 63, range 5120 days) during hospitalizations or as outpatients. 76% of patients received PAP with Aspergillus activity and 79% was admitted to special care unit environment. The ID of invasive mold (IMI) and yeast (IYI) infections were low (0.7 and 0.5/1000 prophylactic days respectively). Significant difference in the ID of documented IFI was detected between echinocandin (5.3/1000 prophylactic days) vs. triazole (voriconazole or posaconazole) (0.4/1000 prophylactic days)-based drugs (p
2012

abstract No: 

1298

Full conference title: 

ID Week 2012
    • IDWeek 2012